HOME >> MEDICINE >> NEWS
GroPep to pursue promising asthma drug following preclinical study results

Adelaide biotechnology company GroPep has completed preclinical efficacy studies of its T-cell peptide drug candidate, in models of psoriasis and asthma.

GroPep will undertake a market feasibility assessment for the use of the drug in asthma but will cease development for psoriasis.

Current annual sales of asthma drugs in the United States alone exceed US$4.0 billion and are growing at over 10%. GroPep has international patent coverage for the T-cell peptide technology.

Listed biopharmaceutical company GroPep Limited (ASX: GRO) announced today that it had completed testing of its T-cell peptide drug candidate in preclinical models of asthma and psoriasis.

The results showed that the drug was highly effective in treating asthma but had little effect in a model of psoriasis when applied to the skin, even in an efficient formulation. As a result, the Company will direct its resources in the highly profitable field of immune-based diseases towards asthma, and will cease development for psoriasis.

As previously reported by the Company, initial research conducted at the Royal North Shore Hospital, Sydney by Professor Manolios showed the drug has potential in a range of autoimmune diseases.

Exclusive, worldwide rights to key patents covering the drug were obtained by GroPep in 2002, through a licence from the Northern Sydney and Central Coast Area Health Service.

In May 2005, GroPep filed a new International Patent Application on the use of the drug for the treatment of asthma, based on the work of Professor Enk at the University of Mainz, Germany Asthma affects more than 15 million people in the US alone and 100 million people worldwide. The market is increasing because of an ageing population and the contribution of pollution, smoking and airborne allergens. Current sales of asthma drugs in the United States alone exceed US$4.0 billion and are growing annually at over 10%.

GroPep's Chief Operat
'"/>

Contact: Tony Mitchell
61-883-547-700
Research Australia
14-Dec-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep completes final milestone of the path malaria vaccine initiative
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Half of active children pursue non-traditional physical activities
7. ICSU pursues new initiative that challenges science to do more to prevent natural disasters
8. Study shows Philip Morris pursued tobacco regulation to enhance its image
9. Study: Directly observed HIV therapy for children is promising
10. Childhood obesity intervention shows promising results
11. Animal study identifies promising new target for brain tumor therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... SAN ANTONIO (PRWEB) , ... August 21, 2019 , ... ... in skin care products. This water-based ingredient is currently used in skincare products such ... with PPT. The award-winning product addresses the growing need to protect the skin from ...
(Date:8/21/2019)... ... August 21, 2019 , ... Future residents got their ... Phase II expansion of Providence Point in Pittsburgh’s Scott Township neighborhood involved additions, ... the 70-unit apartment tower, Hamilton Tower. , The expansion began two ...
(Date:8/19/2019)... MEADOWS, Ill. (PRWEB) , ... August 19, 2019 ... ... performed more than 12.5 million medically necessary and cosmetic procedures in 2018 – ... Now in its seventh year, the 2018 ASDS Survey on Dermatologic Procedures ...
(Date:8/19/2019)... , ... August 19, 2019 , ... A July 26 ... dog owners should be brushing their pets’ teeth twice a day. The acknowledges that, ... the time and suggests that close monitoring and brushing at least twice a week ...
(Date:8/17/2019)... ... August 17, 2019 , ... Approximately 50 area ... services today under a program sponsored by United Concordia Dental and Mission Arlington/Metroplex. ... work alongside them to make these services available to area youths who are ...
Breaking Medicine News(10 mins):
(Date:8/21/2019)... ... August 21, 2019 , ... Dr. Leonard Bley at ... newest laser ReLEx® SMILE (Small Incision Lenticule Extraction) located in their state-of-the-art Manhattan surgery ... SMILE in the Tri-State area. SMILE is a one-step, one laser procedure that is ...
(Date:8/21/2019)... ... 21, 2019 , ... Impact Advisors , a leading provider of clinical, ... has been named to Inc. magazine’s Inc. 5000 list. The Inc. 5000 list is ... percentage revenue growth. This year the firm was also named a 5-Time Inc. 5000 ...
(Date:8/19/2019)... (PRWEB) , ... August 18, 2019 , ... Laurence Fishburne ... all ages across the globe. His work spans genres and generations. On television, he ... a series that covers topics important to today's world and gives viewers information in ...
Breaking Medicine Technology:
Cached News: